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Introduction
Over the past years transversus abdominis plane (TAP) block, a loco regional anaesthesia technique, has become increasingly popular in abdominal surgery because it provides very effective pain relief both pre-and post-operatively thereby reducing postoperative opioid requirement. A local anaesthetic solution is injected into a neurovascular space, between the transverse and internal oblique muscle of the abdomen. The solution anesthetizes the nerves supplying the anterior abdominal wall (T9 to L1) [1, 2] , Figure X. Levobupivacaine is commonly used as an anaesthetic in TAP block. The solution diffuses into the nerve, and causes a reversible block of the sodium channels. This prevents depolarisation and conduction of the nerve action potential. Levobupivacaine local concentration is correlated to its efficiency. But the solution is also absorbed in the systemic and may induce adverse effects (carditoxicity, neurotoxicity) [3] . Absorption from the site of administration is affected by the vascularity of the tissue. Protein binding is upper to 97%. Levobupivacaine is extensively metabolized with no unchanged levobupivacaine detected in urine or faeces. CYP3A4 and CYP1A2 mediate the metabolism of levobupivacaine to desbutyl-levobupivacaine and 3-hydroxy levobupivacaine, respectively The dosing regimen is still empirical in paediatric surgery and rarely based on pharmacokinetic data. In practice, an injected volume of 0.2 à 0.3 ml/kg of levobupivacaine (2.5 mg/ml) is used [4, 5] .
The aim of this work was therefore to describe pharmacokinetics of levobupivacaine and investigate possible sources of between subject variability in children by a population approach when performing an ultrasound-guided TAP block in ambulatory abdominal wall surgery. As the volume of anaesthetic injected could possibly influence its pharmacokinetics [6] , the study was conducted according to two methods of administration: high or low volume of local anaesthetic injected.
Methods
This prospective, randomized, double-blind study protocol was approved by the institutional ethical committee (CPP Sud Mediterranean IV, 2013-A00618-37, Montpellier, France), and registered in Clinical Trials Database (ClinicalTrials.gov. NCT02064088). The written informed consent was obtained from the parents or legal guardians of all participating subjects before randomization.
Patients
Children from 1 to 5 years old (14 to 71 months) and planned for inguinal surgery were candidate to the study. Exclusion criteria included any contraindication to general anaesthesia or TAP block, amide local anaesthetic drug allergy, American Society of Anesthesiologists physical status 3 and 4, nonsteroidal anti-inflammatory drug intolerance, known cardiac / renal / hepatic dysfunction, parental refusal, and concurrent participation to another clinical trial.
Study design and sampling protocol
Each patient received 0.4 mg/kg of levobupivacaine (Chirocaine®, Abbott, Rungis, France) [7] and were assigned to one of the two study groups using a computer generated random sequence. In group 1 (20 patients), the volume of the local anaesthesia solution was adjusted to 0.2 mL/kg of 0.2% levobupivacaine (low volume/high concentration). In group 2 (20 patients), the volume of the local anaesthesia solution was adjusted to 0.4 mL/kg of 0.1% levobupivacaine (high volume/low concentration). Blood samples were collected at 5, 15, 20, 25, 30, 45, 60 and 75 min following the block injection. To quantify the unbound fraction of levobupivacaine, orosomucoid (α1-acid glycoprotein) plasma was immediately ultra-filtrated (cut-off 30 kDa, Ultracel®, Merck Millipore®, Tullagreen, Ireland) at room temperature and stored at -20°C until analysis. For plasma, the assay was done by simple protein precipitation in acetonitrile with added internal standard (etidocaine) and dilution in the mobile phase. The analysis of the prepared samples was performed by liquid chromatography combined with a hybrid triple quadrupole trap mass spectrometer (3200 Qtrap, ABSciex®, Les Ulis, France). Free levobupivacaine concentrations were analyzed by direct injection of the ultra-filtrated serum. According to a previously published method regarding ropivacaïne, the interand intra-day percentage coefficients of variation were below 8 % and 6%, respectively. The lowest limit of quantification (LLOQs) was 1 ng/ml [8] .
Pharmacokinetic analysis
Pharmacokinetic analysis was performed with total concentrations of levobupivacaine, by non-linear mixed-effects modelling using NONMEM® version 7.4 (ICON Development Solutions, MD, USA).
Based on a visual inspection of the individual pharmacokinetic profiles and a review of the literature, one-and two-compartment models were considered to describe the concentration-time data. Different kinetics of absorption (zero-or first-order) were investigated. The between-subject variability (BSV) for each model parameter was modelled using Equation 1 :
where Ρi is the value of the parameter "(e.g., ka or absorption rate constant, CL or clearance, V or volume of distribution) for the ith patient, Ppop is the value of the population parameter and η is the random variable. Usual error models (additive, proportional and combined) were evaluated to describe residual unexplained variability during the screening step. The BSV is modelled in terms of random effect (η) variables. Each of these variables is assumed to have mean 0 and a variance denoted by 
Model evaluation
The robustness of the model and the accuracy of parameters estimates were assessed using a bootstrap method [9] . The entire procedure was undertaken in an automated fashion. From the original dataset, 1 000 bootstrap sets were drawn with re-sampling. For each of the 1 000 bootstrap sets, the pharmacokinetic population parameters were estimated. The corresponding mean, median, standard deviation, 2.5 and 97.5th percentiles were calculated. Visual predictive checks (VPC) [10] were also performed to ensure that simulations based on model could reproduce the observed data. Perlspeaks-NONMEM Tools were used for both VPC and bootstrap evaluation [11] .
Computation of individual exposures
Based on Empirical Bayes Estimates (EBE), single dose exposure values were calculated: i) area under the concentration versus time curve: 0
iii) time to reach Cmax : = ( ) ( − ) ⁄ .
TAP effectiveness evaluation
The cutaneous incision was allowed after a minimum of 15 minutes post TAP injection. Insufficient block (TAP block failure) was defined as an increase of either heart rate or mean arterial blood pressure ≥ 20% at the skin incision, compared to reference values prior block placement. In case of insufficient block, remifentanil infusion was used as backup.
Statistical analysis
Standard statistical tests (t-test, independent Wilcoxon or Fisher's Exact Test) were performed to compare the two groups "TAP Successful" and "TAP Failed". All the pharmacokinetic parameters and exposure values were compared between the two groups. Statistical analyses were performed using R version 3.5.1.
Results

Pharmacokinetic analysis
A total of 247 sample points from 40 subjects were included in the dataset. All the concentrations under the low limit of quantification (LLOQ = 0.05 mg/L) were considered as missing values (MDV=1).
The data were best described by a one-compartment model parameterized in terms of an absorption rate constant (ka, h-1) characterizing the first-order absorption process from the depot to the central compartment, an apparent distribution volume (V/F, L) and clearance (CL/F). The residual unexplained variability was described with a proportional error model (Equation 2):
where Ci is the concentration observed to the ith time and Cpred the concentration predicted by the model.
Weight significantly decreased the objective function and BSV (from 50 to 41%) of clearance and was integrated as covariate:
. (3) Where Cli is the clearance for the ith individual and Cl the value of population clearance.
Population pharmacokinetic parameters are presented in Table 2 . Figure 1 clearance, V: volume of distribution of central compartment, ka first-order absorption rate constant.
Pharmacodynamics of levobupivacaine
Among the 40 patients, none of the 1 to 5 years-old children presented toxicity signs. An insufficient TAP block anaesthesia was obtained for 13 patients and a total anaesthesia was obtained for 27 patients. Pharmacokinetic parameters were not significantly different between the two groups:
effective TAP block versus failed TAP block. PK profiles are presented in Supplementary Data. But we observed that gender and effectiveness of TAP block were dependent variables. (Fisher's Exact Test, p-value = 0.03).
Discussion
Levobupivacaine 0.25% can be administered with doses ranging up to 1 mL/kg [4, 5, 7, [12] [13] [14] [15] .These recommendations are rarely based on pharmacokinetic data. Previous studies with ropivacaine showed an influence of the injected volume on the effectiveness of regional anaesthesia [6, 16] while no study investigated the influence of the injected volume of levobupivacaine during a TAP block. The purpose of this work was to describe the pharmacokinetics of levobupivacaine in children and investigate possible sources of between subject variability including volumes of solution injected (small volume/high concentration or high volume/low concentration) during TAP block.
The absorption rate from TAP to systemic circulation is fast, with a mean absorption half-life = 6 min.
BSV on Ka has been estimated at 81 %. The forward inclusion-backward elimination method did not identify a covariate for Ka, and particularly the injected volume considered as categorical covariate (high/low injected volume). So, from our results, the injected volume does not influence Ka.
Bioavailability factor (F) for "high volume injected" group is comparable to "small volume injected" group (F=0.88, [0.59-1.17]). It is important to note that whatever the group, the injected volumes were low (1.8 to 8.4 mL), which can lead more difficult to highlight difference. Apparent clearance (CL/F) was estimated at 0.15 L/min. This value is higher than the clearance reported for younger children during epidural block [17] . This is coherent with pharmacokinetics of levobupivacaine, metabolized by CYP3A4 and CYP1A2 isoforms. As the maturation of enzyme producing organs increases with age, an increase of mature cytochromes involve a higher clearance. We found a BSV on clearance and distribution volume similar to that reported by Chalkiadis et al. (epidural regional block, with a BSV for V and CL of 48.5% and 35.2% respectively) [17] . Our results confirm that weight must be considered when determining the dose in children.
The dosing regimen of 0.4 mg/kg is safe, no signs of toxicity were observed during the study. But an optimization can be done in terms of efficacy: TAP block effectiveness (15 min post injection) was inadequate for 13 patients out of 40. We have tried to establish a pharmacokinetic/pharmacodynamic (PKPD) model but PK parameters and efficacy were not correlated (Emax, Hill or Logit function). This finding is not surprising given that is an a posteriori analysis, the study was not designed for a PKPD analysis. The only PD endpoint was the increase of either heart rate or arterial blood pressure at the skin incision time (approximatively 15 min post injection), compared to reference values prior block placement. If the heart rate or arterial blood pressure increased, the TAP block was considered as failed (DV = 0). If they were stable, the TAP block was considered as successful (DV = 1). A PKPD model could not be establish without several and accurate PD endpoints available. We observed a significant difference in response to anaesthesia with a higher rate of success for girls (91.7%) than for boys (57.1%). One possible explanation for this difference could be related to weight. On average, girls had slightly higher weight than boys (15.7 kg for girls versus 14.6 kg for boys) and therefore received a higher dose into the deposit site (dose = 0.4 mg/kg). From the pharmacokinetic profiles, the plasma concentrations observed (Cmax = 0.315 mg/L and Cu,max = 3.15 µg/L, respectively) are lower than concentrations considered to be well tolerated for adults (2-4 mg/L and 110-300 µg/L, respectively [18] ), even for an outlier patient (Cmax = 1.29 mg/L) ( Figure 3 ). Considering these results, an adjustment of dosage could be considered for children, in order to improve efficiency of analgesia. or for failed TAP block (pink line).
Conclusion
The optimal dosing regimen of levobupivacaine for an effective TAP block has not been reported in the literature and is still explored [19] . In paediatrics, even though recommendations exist, the optimal dose to be administered is not clearly established and is still empirical. At 0.4 mg/kg, none of the 1 to 5 years-old children presented toxicity signs and there is some clues that this dose could be increased, to obtain a better efficacy. Finally children's weight must be considered to evaluate their clearance and thus to anticipate any risk of toxicity.
